MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
bovnews2d
BTIG Research Just Downgraded Fiverr International Ltd (FVRR) Stock—What Does This Mean for Investors?
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
Palo Alto Networks shares fall as Deutsche Bank, BTIG downgrade rating
Shares of Palo Alto Networks (NASDAQ:PANW) fell more than 2% in premarket trading Wednesday after analysts at BTIG and ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
bovnews12h
Ready Capital Corp (RC) Posted -12.24% Profit Margin Last Year—Can It Hold Up?
On Wednesday, Ready Capital Corp (RC) stock saw a decline, ending the day at $6.66 which represents a decrease of $-0.20 or -2.92% from the prior close of $6.86. The stock opened at $6.82 and touched ...
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend Winners
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they could rally this year.
Traders Magazine9y
BTIG Expands Transition Management, Hires Howell to Boost Business
BTIG is growing its transition management business and hired a senior executive to help boost business. The firm has hired Daniel Howell as a director who will be based in New York. His job is ...
Here are some of BTIG's top picks for the first half of 2025
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
Boston Scientific price target raised to $101 from $97 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...
The market is suffering from a 'three-body problem,' says BTIG's Jonathan Krinsky
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
Investing10d
BTIG sees a risk for 'a bigger January decline' in S&P 500
According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...